BACKGROUND: Ex vivo expansion of cord blood (CB) hematopoietic stem and progenitor cells increases cell dose and may reduce the severity and duration of @entity1398 and @entity882 after transplantation. This study's purpose was to establish a clinically applicable culture system by investigating the use of cytokines, serum-free media, and autologous plasma for the expansion of CB cells and the engraftment of expanded product in nonobese @entity6 /severe combined @entity465 ( @entity9719 / @entity915 ) @entity19 . STUDY DESIGN AND METHODS: Enriched CB @entity22416 + cells were cultured in four media (Iscove's modified Dulbecco's medium with FCS, Gibco; X-Vivo-10, BioWhittaker; QBSF-60, Quality Biological; and StemSpan SFEM, Stem Cell Technologies) with four cytokine combinations (thrombopoietin [TPO], @entity10898 , @entity24817 [FL] with and without @entity24778 , and/or @entity777 ). The effect of autologous CB plasma was also investigated. The read-out measures were evaluated on Days 8 and 12. After expansion at the optimized condition, cultured cells were transplanted into sublethally irradiated @entity9719 / @entity915 @entity19 . The engraftment of @entity1 @entity1195 + cells and subsets in the bone marrow, spleen, and peripheral blood was determined. RESULTS: QBSF-60 or StemSpan SFEM supported high yields of early progenitors ( @entity22416 + cells, <or= 64.8-fold; @entity22416 + @entity53017 - cells, 330-fold; CFU-granulocyte erythroid macrophage megakaryocyte [GEMM], 248-fold) and CFUs of the myeloid (CFU-GM, 407-fold) and erythroid (BFU/CFU-E, 144-fold) lineages. The expansion of the megakaryocytic lineage was consistently higher in X-Vivo-10 (CFU-megakaryocyte, 684-fold). Autologous plasma promoted colony formation but reduced @entity22416 + cells and CFU-GEMM. The addition of @entity24778 or @entity777 improved cell yields; @entity24778 was more effective for committed progenitors. Expansion products from cultures in QBSF-60 with the cytokines engrafted and differentiated into the myeloid and lymphoid lineages in @entity9719 / @entity915 @entity19 . CONCLUSION: The data supported the strategy of expansion. The optimized condition may be applicable to clinical expansion for the @entity1503 .

Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in @entity9719 / XXXX @entity19 .

@entity10898 :: ('17311(Tax:10090)', 'Gene') :: ['SCF'] @entity1 :: ('9606', 'Species') :: ['human'] @entity53017 :: ('12494(Tax:10090)', 'Gene') :: ['CD38'] @entity9719 :: ('MESH:D020191', 'Disease') :: ['NOD'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity24778 :: ('12985(Tax:10090)', 'Gene') :: ['G-CSF'] @entity24817 :: ('14256(Tax:10090)', 'Gene') :: ['Flt-3 ligand'] @entity1195 :: ('5788', 'Gene') :: ['CD45'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['abrogation or reduction of posttransplant cytopenia'] @entity915 :: ('MESH:D053632', 'Disease') :: ['SCID'] @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficient'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity777 :: ('16193(Tax:10090)', 'Gene') :: ['IL-6'] @entity22416 :: ('12490(Tax:10090)', 'Gene') :: ['CD34']
@entity915 :: (MESH:D053632,Disease) :: ['SCID']
